On 22-23 November, Novo Nordisk announced the completion and results of its Pioneer 9 and Pioneer 6 phase 3a trials, both conducted with an oral semaglutide, a once-daily oral formulation of the long-acting GLP-1.
Novo Nordisk announced the completion and results on Thursday, November 22 and Friday, November 23 regarding their Pioneer 9 and Pioneer 6 phase 3a trials, both conducted with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog. Both studies utilized Emisphere Technologies, Inc. (“Emisphere” or the “Company”) (OTCBB: EMIS) proprietary Eligen® SNAC Carrier Technology. These two clinical trials represent the completion of Novo Nordisk’s ten-study Pioneer phase 3a oral semaglutide clinical program.
A copy of the detailed Novo Nordisk’s study announcements on the Pioneer 9 and Pioneer 6 studies can be viewed at the following respective links:
https://www.novonordisk.com/bin/getPDF.2226662.pdf
https://www.novonordisk.com/bin/getPDF.2226789.pdf